Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Eli Lilly

Eli Lilly and Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announces top-line results from Phase 3 BRAVE-AA2 study evaluating baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). AA is an autoimmune disorder that usually results in unpredictable, patchy hair loss.

Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder

INDIANAPOLIS, March 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA)....

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Agree Realty

Avis Budget Group

Zoetis

American Assets

Molecular Templates

OPKO Health

Royalty Pharma

Sonos

United States Lime & Minerals, Inc.

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Validation by the EMA of Marketing Authorization Application for Retifanlimab as a Treatment for Squamous Cell Anal Carcinoma (SCAC)

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of sNDA for Jakafi (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease

Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease

Under Priority Review status, the FDA has accepted Incyte Corporation's (NASDAQ: INCY) marketing application for review seeking approval for ruxolitinib cream. Ruxolitinib is a selective JAK1/JAK2 inhibitor as a treatment for atopic dermatitis, a type of eczema characterized by inflammation and intense itch.

FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

Incyte was a buy, with share price at $85.61 in December 2020.

Incyte: Another Buy Opportunity

Nordstrom

Lyft

Twitter

Freeport-McMoRan

Barrick Gold

Goodyear Tire & Rubber

Jack in the Box

With the trading day about halfway over, the broad markets had pulled back slightly on Wednesday.

Barrick, Lyft, Nordstrom, Twitter and More Wednesday Afternoon Analyst Calls

Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q4 2020 Results - Earnings Call Transcript

Several products contributed to the biotech's solid growth.

What's Behind Incyte's Better-Than-Expected Q4 Earnings

Incyte (INCY) delivered earnings and revenue surprises of 13.41% and 17.87%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Q4 Earnings and Revenues Top Estimates

Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 43.08% over the past year to $0.93, which beat the estimate of $0.75.

Recap: Incyte Q4 Earnings

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive CHMP opinion for Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic CCA with FGFR2 fusion or rearrangement

Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.

Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2020 Press Release: February 9, 2021 at 7:00 a.m. ET • Q4 & YE 2020 Conference Call: February 9, 2021 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-

Incyte to Report Fourth Quarter and Year-End 2020 Financial Results

Morphosys AG - ADR

PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).

MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.

Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment

Altimmune

BioCardia Inc.

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune is a U.S.-based, clinical-stage immunotherapeutic biotechnology company.

Why These Health Care Stocks Are Moving Today

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804

Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

News for Incyte Stock (INCY)